Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.

Cadastre-se

RVNC Revance Therapeutics Inc

3,65

0,00 (0,00%)

Pré-mercado

Última atualização: 06:00:00

Atrasado em 15 minutos

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Revance Therapeutics (NASDAQ:RVNC)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025

Click aqui para mais gráficos Revance Therapeutics.

Revance Therapeutics (NASDAQ:RVNC)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025

Click aqui para mais gráficos Revance Therapeutics.

Notícias Revance Therapeutics Inc

Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact The Gross Law Firm about pending Class Action - RVNC
Segunda, 3 de Fevereiro de 2025 (2 dias atrás) • PR Newswire (US)

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Sexta, 31 de Janeiro de 2025 (5 dias atrás) • Edgar (US Regulatory)

Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
Sexta, 31 de Janeiro de 2025 (5 dias atrás) • Edgar (US Regulatory)

Revance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th Deadline
Sexta, 31 de Janeiro de 2025 (5 dias atrás) • PR Newswire (US)

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Quinta, 30 de Janeiro de 2025 (6 dias atrás) • Edgar (US Regulatory)

The Gross Law Firm Reminds Revance Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
Quinta, 30 de Janeiro de 2025 (6 dias atrás) • PR Newswire (US)

Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
Segunda, 27 de Janeiro de 2025 (1 semana atrás) • PR Newswire (US)

Shareholders of Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNC
Quinta, 23 de Janeiro de 2025 (2 semanas atrás) • PR Newswire (US)

Form SC 14D9/A - Solicitation, recommendation statements: [Amend]
Terça, 21 de Janeiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
Terça, 21 de Janeiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Form 8-K - Current report
Terça, 21 de Janeiro de 2025 (2 semanas atrás) • Edgar (US Regulatory)

Crown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender Offer
Terça, 21 de Janeiro de 2025 (2 semanas atrás) • PR Newswire (US)

Mais Notícias de Revance Therapeutics Inc

Índice Bovespa

Grupo Casas Bahia ON

PET MANGUINH ON

LOJAS MARISA ON

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições